Indication intelligence, analysis and sector perception

Cytori (CYTX) 8.6 M share offering priced at $1.10 after stock jumps on BARDA news

April 10, 2017 4:52pm

After a 25.55% (+$0.35) advance, CYTX launched a secondary offering. Share pricing fell -34.30% (-$0.61) at the open

CYTX secured approval from the U.S. FDA for an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate its Cytori Cell Therapy in patients with thermal burn injury.

The contract was originally signed in the year 2014, and was extended in September 2016 to facilitate continued funding of CYTX’s ongoing investigation and development for treating thermal burn injuries. Under the provision, Cytori can request BARDA for additional financing to cover costs for completing pilot clinical trial after achieving Investigational Device Exemption (IDE) approval from the FDA.

With only two (2) quarters of cash left (spending $4.2 M a quarter) – it was a MUST.

The last offering, a rights offering at $2.55 raised $17.6 M and was priced at $2.77 – ten (10) months ago …

The discount was DEEP priced at $1.10 and at the open was trading at $1.14 (-$0.59) - UGLY

With 23.6 M shares outstanding, the offering would increase the total by 36.5%

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.